TRPX - Therapix Biosciences Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.5200
+0.0424 (+8.88%)
At close: 4:00PM EDT

0.5199 -0.00 (-0.02%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.4776
Open0.4950
Bid0.5098 x 1200
Ask0.5144 x 800
Day's Range0.4620 - 0.5598
52 Week Range0.2520 - 4.6900
Volume3,276,663
Avg. Volume1,995,387
Market Cap2.974M
Beta (5Y Monthly)0.12
PE Ratio (TTM)N/A
EPS (TTM)-2.7980
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Pure Capital Demands Replacement of Therapix Biosciences Ltd.'s Board of Directors

    Pure Capital today announces that it has sent a letter to the chief executive officer, chairman of the board and the directors of Therapix Biosciences Ltd. (TRPX), calling for an immediate general meeting of the shareholders of Therapix Biosciences and the dismissal of all members of the board. In the letter, Pure Capital detailed previous actions which it believes have been harmful to shareholders.

  • Therapix Biosciences Closes A Joint Venture Transaction For its Sleep Indication
    PR Newswire

    Therapix Biosciences Closes A Joint Venture Transaction For its Sleep Indication

    Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that it has closed a joint venture transaction for collaboration in the field of developing pharmaceuticals for a sleep-related indication. In addition, the Company has appointed Mr. Arie Webber to its Board of Directors.

  • Therapix Biosciences Appoints Prof. Ari Shamiss (M.D., M.P.A.) to the Company's Board of Directors
    PR Newswire

    Therapix Biosciences Appoints Prof. Ari Shamiss (M.D., M.P.A.) to the Company's Board of Directors

    Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announces today the appointment of Prof. Ari Shamiss (M.D., M.P.A.) to the Company's Board of Directors.

  • Nasdaq Hearings Panel Grants Therapix Biosciences Extension to Regain Compliance With Listing Requirements
    PR Newswire

    Nasdaq Hearings Panel Grants Therapix Biosciences Extension to Regain Compliance With Listing Requirements

    Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that on April 8, 2020, it received notice that the Nasdaq Hearings Panel (the "Panel") granted the Company an extension until May 18, 2020, to regain compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement").

  • Therapix Biosciences Announces Appointment of New CEO
    PR Newswire

    Therapix Biosciences Announces Appointment of New CEO

    Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today the appointment of Mr. Gilad Bar-Lev as CEO of the Company, effective as of May 6, 2020. Mr. Bar-Lev will replace Dr. Ascher Shmulewitz at his position as the interim CEO of the Company. Dr. Shmulewitz will continue to serve as the Chairman of the Company's Board of Directors.

  • Therapix Biosciences Announces Pricing of $1.25 Million Public Offering
    PR Newswire

    Therapix Biosciences Announces Pricing of $1.25 Million Public Offering

    Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced the pricing of a public offering for the issuance of an aggregate of 4,166,668 units, each consisting of (i) one pre-funded warrant to purchase one American depositary share ("ADS") and (ii) one Series B warrant to purchase one ADS, at a purchase price of $0.2999 per unit. The Series B warrants will have an exercise price of $0.43 per ADS, will be exercisable upon issuance and will expire five years from the date of issuance.

  • Therapix Biosciences Ltd. Announces Shareholder Conference Call
    PR Newswire

    Therapix Biosciences Ltd. Announces Shareholder Conference Call

    Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that the Company will host a conference call on Wednesday, April 22, 2020, at 4:30 PM EDT. ET

  • Therapix Biosciences Ltd. Signs Securities Purchase Agreement
    PR Newswire

    Therapix Biosciences Ltd. Signs Securities Purchase Agreement

    Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that it has entered into a securities purchase agreement pursuant to which it will make a private placement (the "Private Placement") to its Chairman and Interim Chief Executive officer of convertible promissory notes (the "Notes") with an aggregate original principal amount of approximately $350,000 (the "Principal Amount"), at an aggregate purchase price of $315,000 (the "Purchase Price") in several tranches, spread across a 12 month period. In addition, the Company will issue a warrant to purchase up to 314,285 American Depositary Shares ("ADSs") of the Company (the "Warrant") and 40,000 ADSs. The initial tranche of the Private Placement is for a Principal Amount of $220,000 at a Purchase Price of $198,000.

  • Therapix Biosciences Ltd. Receives Nasdaq Notification Regarding Minimum Bid Requirements
    PR Newswire

    Therapix Biosciences Ltd. Receives Nasdaq Notification Regarding Minimum Bid Requirements

    Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that on February 24, 2020, the Company received a written notice from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company's closing bid price for its American Depositary Shares was below $1.00 per share for the last 30 consecutive business days.

  • Therapix Biosciences Announces Pricing of $1,250,000 Registered Direct Offering
    PR Newswire

    Therapix Biosciences Announces Pricing of $1,250,000 Registered Direct Offering

    Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced that it has entered into definitive agreements with several accredited and institutional investors providing for the issuance of an aggregate of 1,000,000 American depositary shares ("ADSs") at a purchase price of $1.25 per ADS in a registered direct offering.

  • Therapix Biosciences Announces the Continued Development of THX-210 ("RESPECTRUM") Cannabinoids Based Treatment for Autism Spectrum Disorder
    PR Newswire

    Therapix Biosciences Announces the Continued Development of THX-210 ("RESPECTRUM") Cannabinoids Based Treatment for Autism Spectrum Disorder

    Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today the progression of its RESPECTRUM product candidate into clinical stage. The company plans to initiate a randomized, double blind placebo controlled study to evaluate the efficacy, safety and tolerability of RESPECTRUM in treating patients with Autism Spectrum Disorder (ASD). The trial objective is to assess the efficacy and safety of RESPECTRUM versus cannabidiol (CBD)-rich oil by ASD severity measurements. Patient population is expected to include autistic subjects aged five to 35, and is based on the "entourage effect" phenomenon, hence the company expects improved efficacy, safety and tolerability over CBD alone.

  • Benzinga

    The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 20) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY )(announced ...

  • Therapix Biosciences Announces Receipt of Notice of Delisting From Nasdaq and Intention to Appeal
    PR Newswire

    Therapix Biosciences Announces Receipt of Notice of Delisting From Nasdaq and Intention to Appeal

    TEL AVIV, Israel, Nov. 20, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that it received a written Notice of Delisting from the Listing Qualifications Department of The Nasdaq Capital Market ("Nasdaq"). The Company intends to appeal this decision by requesting a hearing before a Nasdaq Hearings Panel to review Nasdaq's decision to delist the Company.

  • Benzinga

    Therapix Pursues Reverse Merger With CBD Wellness Company Heavenly Rx

    Cannabis-focused investment company SOL Global Investments Corp. (CSE: SOL) (OTC: SOLCF) said Tuesday that its portfolio company, Heavenly Rx, Ltd., has entered into a memorandum of understanding with Therapix Biosciences Ltd (NASDAQ: TRPX) to chase a business combination. Therapix Biosciences is a pharmaceutical company with a portfolio of technologies based on cannabinoid pharmaceuticals. Under the MOU, both companies will further discuss a final agreement for a business combination, which includes a reverse takeover of Therapix by Heavenly Rx.

  • SOL Global Portfolio Company Heavenly Rx, Ltd. Enters Into MOU for Business Combination with Therapix Biosciences
    CNW Group

    SOL Global Portfolio Company Heavenly Rx, Ltd. Enters Into MOU for Business Combination with Therapix Biosciences

    TORONTO , Nov. 19, 2019 /CNW/ - SOL Global Investments Corp. ("SOL Global" or the "Company") (SOL.CN) (SOLCF) (9SB.F) announced today that its 40.7% owned portfolio company Heavenly  Rx, Ltd. ("Heavenly Rx") has entered into a memorandum of understanding ("MOU") with the US NASDAQ listed public company, Therapix Biosciences Ltd (TRPX), a speciality clinical-stage pharmaceutical company with a portfolio of technologies and assets based on cannabinoid pharmaceuticals, pursuant to which Therapix and Heavenly Rx have agreed to pursue a business combination. Pursuant to the MOU, the parties will negotiate a definitive agreement for a business combination between Therapix and Heavenly Rx, constituting a reverse takeover of Therapix by Heavenly Rx.

  • Benzinga

    The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...

  • Therapix Biosciences Enters Into MOU for Business Combination With Heavenly Rx, Ltd.
    PR Newswire

    Therapix Biosciences Enters Into MOU for Business Combination With Heavenly Rx, Ltd.

    TEL AVIV, Israel, Nov. 18, 2019 Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), announced today that it entered into a memorandum of understanding ("MOU") with Heavenly Rx, Ltd. ("Heavenly Rx"), an emerging consumer hemp CBD company, pursuant to which Therapix and Heavenly Rx have agreed to pursue a business combination.

  • Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program
    PR Newswire

    Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program

    TEL AVIV, Israel, Nov. 13, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today topline results from its Phase IIa clinical study at Assuta Hashalom Medical Center in Israel, suggesting that THX-110, a combination of dronabinol (∆ -9-tetrahydracannabinol, THC) and CannAmide™ (palmitoylethanolamide, PEA), positively affects symptoms in adult subjects with obstructive sleep apnea (OSA).

  • Benzinga

    The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ...

  • Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger
    PR Newswire

    Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger

    TEL AVIV, Israel, Nov. 7, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, along with Destiny Biosciences Global Corp. ("Destiny"), announced today the mutual decision to discontinue negotiations on the previously announced proposed merger. On July 23, 2019, Therapix announced the signing of a Letter of Intent for a proposed merger with Destiny. According to the Letter of Intent, the parties agreed to allow until October 31, 2019 to complete definitive agreements before abandoning the transaction.

  • Therapix Biosciences Announces Positive Data From Recent Pre-clinical Study for New Drug Candidate THX-210
    PR Newswire

    Therapix Biosciences Announces Positive Data From Recent Pre-clinical Study for New Drug Candidate THX-210

    TEL AVIV, Israel, Oct. 15, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today positive results in its pre-clinical study evaluating THX-210, a proprietary novel pharmaceutical preparation containing non-psychoactive cannabinoid cannabidiol (CBD) and palmitoylethanolamide (PEA). THX-210 is intended for the treatment of epilepsy, as well as inflammatory conditions. The study consisted of in vitro tests which examined potential synergy between CBD and PEA.

  • Benzinga

    The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout

    The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra ...

  • Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp.
    PR Newswire

    Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp.

    TEL AVIV, Israel, Oct. 10, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today an update on its planned merger with Destiny Biosciences Global Corp. ("Destiny"). On July 23, 2019, Therapix announced the signing of a Letter of Intent for a proposed merger with Destiny. If completed, the transaction will create a combined company that focuses on Therapix's proprietary IP and related technology, and assets pertaining to all clinical stage pharmaceutical applications and Destiny's genomics-based breeding techniques and development capabilities.

  • Nasdaq Grants Therapix Biosciences Extension to Comply With Stockholders' Equity Requirement
    PR Newswire

    Nasdaq Grants Therapix Biosciences Extension to Comply With Stockholders' Equity Requirement

    TEL AVIV, Israel, Aug. 27, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that the Nasdaq Stock Market has granted the Company an extension until November 18, 2019, to regain compliance with Nasdaq Listing Rule 5550(b)(1), which will permit the continued listing of Therapix's stock on the Nasdaq Stock Market. As previously reported on May 23, 2019, Therapix received a letter notifying the Company that the stockholders' equity reported in the Company's Annual Report on Form 20-F for the year ended December 31, 2018, was below the minimum stockholders' equity of $2,500,000 required for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq listing rule 5550(b)(1).

  • Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide™), a Non-Opiate Based Pain Management Supplement
    PR Newswire

    Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide™), a Non-Opiate Based Pain Management Supplement

    This license is issued by Health Canada under the authority of the Natural Health Products Regulations. Dosage form of the described natural health product is tablets composed of 400mg PEA with a recommended dose of 1 tablet 3 times daily.